Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 26, 2017

DrugPatentWatch Database Preview

HYDROXYPROGESTERONE CAPROATE Drug Profile

« Back to Dashboard

What is the patent landscape for Hydroxyprogesterone Caproate, and what generic Hydroxyprogesterone Caproate alternatives are available?

Hydroxyprogesterone Caproate is a drug marketed by Akorn, Allergan Sales Llc, and Aspen Global Inc. and is included in three NDAs.

The generic ingredient in HYDROXYPROGESTERONE CAPROATE is hydroxyprogesterone caproate. There are eleven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydroxyprogesterone caproate profile page.

Summary for Tradename: HYDROXYPROGESTERONE CAPROATE

Patents:0
Applicants:3
NDAs:3
Suppliers / Packagers: see list1
Bulk Api Vendors: see list44
Clinical Trials: see list18
Patent Applications: see list2,750
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:HYDROXYPROGESTERONE CAPROATE at DailyMed

Pharmacology for Tradename: HYDROXYPROGESTERONE CAPROATE

Ingredient-typeProgesterone Congeners
Drug ClassProgestin
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akorn
HYDROXYPROGESTERONE CAPROATE
hydroxyprogesterone caproate
INJECTABLE;INJECTION018004-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Aspen Global Inc
HYDROXYPROGESTERONE CAPROATE
hydroxyprogesterone caproate
INJECTABLE;INJECTION200271-001Aug 24, 2015RXNoYes► Subscribe► Subscribe
Allergan Sales Llc
HYDROXYPROGESTERONE CAPROATE
hydroxyprogesterone caproate
INJECTABLE;INJECTION017439-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Allergan Sales Llc
HYDROXYPROGESTERONE CAPROATE
hydroxyprogesterone caproate
INJECTABLE;INJECTION017439-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Uncover prior art in abandoned patent applications and expired patents
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot